Neonatal diabetes mellitus: a disease linked to multiple mechanisms by Michel Polak & Hélène Cavé
BioMed Central
Orphanet Journal of Rare Diseases
ssOpen AcceReview
Neonatal diabetes mellitus: a disease linked to multiple 
mechanisms
Michel Polak*1 and Hélène Cavé2
Address: 1Faculty of medicine Paris René Descartes, Paediatric endocrinology and INSERM U845, Hôpital Necker-Enfants Malades, 149 rue de 
Sèvres, Paris, France and 2Département de Génétique, Hôpital Robert Debré, 48 Boulevard Sérurier, 75019 Paris, France
Email: Michel Polak* - michel.polak@nck.aphp.fr; Hélène Cavé - helene.cave@rdb.aphp.fr
* Corresponding author    
Abstract
Transient (TNDM) and Permanent (PNDM) Neonatal Diabetes Mellitus are rare conditions
occurring in 1:300,000–400,000 live births. TNDM infants develop diabetes in the first few weeks
of life but go into remission in a few months, with possible relapse to a permanent diabetes state
usually around adolescence or as adults. The pancreatic dysfunction in this condition may be
maintained throughout life, with relapse initiated at times of metabolic stress such as puberty or
pregnancy. In PNDM, insulin secretory failure occurs in the late fetal or early post-natal period and
does not go into remission. Patients with TNDM are more likely to have intrauterine growth
retardation and less likely to develop ketoacidosis than patients with PNDM. In TNDM, patients
are younger at the diagnosis of diabetes and have lower initial insulin requirements. Considerable
overlap occurs between the two groups, so that TNDM cannot be distinguished from PNDM based
on clinical features. Very early onset diabetes mellitus seems to be unrelated to autoimmunity in
most instances. A number of conditions are associated with PNDM, some of which have been
elucidated at the molecular level. Among these, the very recently elucidated mutations in the
KCNJ11 and ABCC8 genes, encoding the Kir6.2 and SUR1 subunit of the pancreatic KATP channel
involved in regulation of insulin secretion, account for one third to half of the PNDM cases.
Molecular analysis of chromosome 6 anomalies (found in more than 60% in TNDM), and the
KCNJ11 and ABCC8 genes encoding Kir6.2 and SUR1, provides a tool to identify TNDM from
PNDM in the neonatal period. This analysis also has potentially important therapeutic
consequences leading to transfer some patients, those with mutations in KCNJ11 and ABCC8 genes,
from insulin therapy to sulfonylureas. Recurrent diabetes is common in patients with "transient"
neonatal diabetes mellitus and, consequently, prolonged follow-up is imperative. Realizing how
difficult it is to take care of a child of this age with diabetes mellitus should prompt clinicians to
transfer these children to specialized centers. Insulin therapy and high caloric intake are the basis
of the treatment. Insulin pump may offer an interesting therapeutic tool in this age group in
experienced hands.
Definition, forms and epidemiology
Neonatal diabetes mellitus (NDM) is a rare (1:300,000–
400,000 newborns) but potentially devastating metabolic
disorder characterized by hyperglycemia combined with
low levels of insulin. Two main groups have been recog-
nized on clinical grounds, transient NDM (TNDM) and
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insulin dependence early in the disease. TNDM is a devel-
opmental disorder of insulin production that resolves
postnatally and represents 50% to 60% of cases of neona-
tal diabetes. There are no clinical features that can predict
whether a neonate with diabetes (but no other dysmor-
phic features) will eventually have permanent or transient
disease. Recently, advances have been made in the under-
standing of the molecular mechanisms of pancreatic
development that are relevant to PNDM and TNDM
(Table 1). This review focuses on the clinical features and
the molecular causes of these varied conditions. It also
underlines how the molecular understanding of some
forms of neonatal diabetes led to transfer patients from
insulin injections to oral sulfonylureas, providing a spec-
tacular example of a pharmacogenomic approach.
I. Clinical description
Neonatal diabetes mellitus presents as hyperglycemia,
failure to thrive and, in some cases, dehydration and
ketoacidosis, which may be severe with coma in a child
within the first months of life. Insulin production is inad-
equate with a low blood level in comparison with the
hyperglycemia, and therefore exogenous insulin therapy
is required.
A. Clinical description of TNDM
TNDM is a developmental disorder of insulin production
that resolves postnatally. TNDM represents 50% to 60%
of cases of neonatal diabetes [1,2]. Intrauterine growth
retardation (IUGR) is usually present. The high rate of
IUGR is in keeping with the crucial role of insulin in fetal
growth, especially during the last trimester of pregnancy.
Hyperglycemia, failure to thrive and, in some cases, dehy-
dration occur after birth. Insulin production is inade-
quate, requiring exogenous insulin therapy. Tests are
negative for anti-islet antibodies and for HLA class II hap-
lotypes conferring susceptibility to type 1 diabetes [2]. A
defect in cell maturation has been suggested [3]. Interest-
ingly, exocrine pancreatic insufficiency is present in only
a few patients [4]. However, the cellular basis of TNDM
remains unknown. Most patients recover within a year,
but a few have persistent glucose intolerance and/or recur-
rence of diabetes in late childhood or adulthood.
Although these recurrences are usually consistent with
non-autoimmune type 1 diabetes, whether they are
ascribable to insulin deficiency and/or insulin resistance
remains unclear [1,2,5]. Indeed, a permanent hyperglyc-
emia requiring insulin therapy developed in five of the
seven TNDM patients who were older than 8 years of age
in a French cohort [6]. Similarly, in another large cohort
of TNDM patients, diabetes mellitus recurred in 11 out of
18 patients older than 4 years of age [7]. Thus, the "tran-
sient" form of the disease is probably a permanent β-cell
defect with variable expression during growth and devel-
opment. A major factor in the onset of recurrent diabetes
is probably puberty, which is associated with significant
insulin resistance.
We examined derived indices of pancreatic β-cell func-
tion, peripheral insulin sensitivity and the pancreatic
response to intravenous glucose loading in children with
a previous history of transient neonatal diabetes currently
in remission repeated after a period of two years [8]. One
child had a sub-normal insulin secretory response to
intravenous glucose that remained abnormal two years
later. The other children had relatively normal or entirely
normal responses over two years. Measures of β-cell func-
tion and insulin sensitivity in the fasting state showed
comparable results to those obtained from normal con-
trols [8]. We concluded that the majority of children with
TNDM in remission have no evidence of β-cell dysfunc-
tion or insulin resistance in the fasting state. Measures of
insulin response to intravenous glucose loading are often
normal but suggestive of future recurrence if profoundly
abnormal [8].
Table 2 compares several clinical features of TNDM and
PNDM in the French cohort (n = 50) [9].
B. Clinical description of PNDM
Permanent neonatal diabetes mellitus is less common
than the transient form of the condition. By definition,
diabetes develops in the neonatal period and does not go
Table 1: Etiologies of neonatal diabetes
Transient neonatal diabetes mellitus Permanent neonatal diabetes mellitus
• Chromosome 6 anomalies detected • Heterozygous activating mutation in KCNJ11 gene and in ABCC8 gene (Kir6.2 and SUR1 




• ABCC8 (SUR1) and rarely KCNJ11 (Kir6.2) mutations • IPEX syndrome: diffuse autoimmunity
• Mitochondrial disease
• Severe pancreatic hypoplasia associated with IPF1 (PDX1) mutation
• Homozygous glucokinase mutation: insensitivity to glucose
• Associated with epiphyseal dysplasia: Wolcott Rallison syndrome
• Possibly associated with enterovirus infection
• Association with cerebellar hypoplasia and PTF1A mutation
• Association with hypothyroidism, glaucoma and GLIS3 mutationPage 2 of 11
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dict whether a neonate with diabetes but no other dys-
morphic features will eventually have permanent or
transient disease, although cases with the permanent form
do not always have IUGR as is universally seen in the tran-
sient 6q phenotype (see below) (Table 2) [6,7]. Diabetes
in infancy is nearly always unrelated to classical type 1
diabetes [10]. In an Italian study conducted in all infants
developing diabetes before the age of one year, a clear dif-
ference was demonstrated between those infants develop-
ing diabetes before the age of 180 days and those after.
The children developing diabetes early had a very high
presence of "protective" HLA alleles against classical type
1 diabetes (76% with 0 or 1 susceptibility heterodimers),
compared to only 12% in the late (>180 days) onset
group [11]. In addition, autoimmune markers were far
less prevalent in the early onset group of children com-
pared to children with late onset diabetes (15% vs 65% if
onset after 180 days).
II. Mechanisms
A. Molecular mechanisms of TNDM
TNDM is usually sporadic, but paternal transmission has
been documented in about one-third of reported patients,
some of whom had non-diabetic fathers [1,12]. Paternal
isodisomy of chromosome 6 has been demonstrated in
several unrelated patients with TNDM (Figure 1). Other
patients had partial duplications of the long arm of the
paternal chromosome 6 [13,14]. When these unbalanced
duplications are inherited within families. TNDM arises
only if the duplication is inherited from the father, sug-
gesting a disorder of imprinting. More recently, a region in
which methylation differs between the maternal and the
paternal chromosome 6 has been identified [14]. Abnor-
mal methylation patterns have been documented in some
TNDM patients without other chromosome 6 abnormali-
ties (Table 1) (Figures 2, 3, 4) [15]. These observations
strongly suggest that TNDM may result from over-expres-
sion of an imprinted gene located on chromosome 6q24
and displaying paternal expression. Two paternally
expressed genes are located in the region and, therefore,
have been considered candidate genes for the disease: one
is the gene encoding transcription factor ZAC (LOT1,
PLAGL-1) that regulates cell cycle arrest and apoptosis and
also the Pituitary Adenylate Cyclase Activating Polypep-
tide Receptor 1 (PACAP1) being a potent insulin secreta-
gogue, and the other is the HYMAI gene, whose function
is unknown [16]. No other loci have been implicated in
TNDM to date. Recently, an animal model of TNDM has
been generated by the insertion of the human TNDM
locus into a mouse. Mice over-expressing the TNDM locus
display many, but not all, of the features of human TNDM
[17]. Paternal transmission leads to neonatal hyperglyc-
emia and an increased tendency for diabetes in later life.
Interestingly, over-expression of the TNDM locus reduces
the expression of the key transcription factor PDX-1 in the
embryonic pancreas of these mice [17]. Nevertheless, the
precise link between those genetic anomalies and the
insulin secreting cell impaired function remained to be
established.
Schematic representation of paternal uniparental disomy of chro osome 6Figure 1
Schematic representation of paternal uniparental disomy of 
chromosome 6. In cases of paternal UPD 6, two alleles are 
inherited from the father.
Table 2: Comparison of several features in PNDM and TNDM cases in the French cohort (n = 50) (adapted from [9]).
PNDM n = 21 TNDM n = 29 P value
Gestational age (weeks) 39.2 ± 1.6 38.2 ± 2.2 P = 0.15
Birth weight (g) 2497 ± 690 1987 ± 510 P < 0.006
Birth length (cm) 47.5 ± 2.4 44.3 ± 3.4 P < 0.006
Head circumference (cm) 33 ± 1.9 31.5 ± 1.8 P < 0.02
Intrauterine growth retardation n = 7/19 36% n = 20/27 74% P < 0.03
Median age at diagnosis (days) (range)* 27 (1–127) 6 (1–81) P < 0.01
Initial insulin dose (unit/kg/day) 1.4 ± 1.2 0.6 ± 0.25 P < 0.006
* Given the non-Gaussian distribution of age in the study population, the nonparametric Mann-Whitney U-test was used to compare age in the two 
groups.Page 3 of 11
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B1. The insulin cell potassium channel (Kir6.2/SUR1) (Figures 5 and 
6)
Mutations in KCNJ11 encoding the Kir6.2 subunit of the
pancreatic ATP-sensitive potassium channels (KATP) cou-
ple cell metabolism to electrical activity by regulating
potassium movement across the membrane. These chan-
nels are made up of an octameric complex with two kind
of subunits: four regulatory sulfonylurea receptors (SUR)
embracing four pore forming inwardly rectifying potas-
sium channels (Kir). A 1:1 SUR1:KIR6.2 stochiometry is
both necessary and sufficient for assembly of active KATP
channels. SUR, a member of the ABC transporter family,
originates from two separate genes and therefore occurs in
several spliced isoforms. SUR1 is found in the pancreatic
β-cells and neurons, whereas SUR2A is in heart cells and
SUR2B in smooth muscle. The Kir6.2 subunit forms the
channel pore in the majority of tissues such as pancreatic
β-cells, brain, heart and skeletal muscles, while Kir6.1 can
be found in smooth vascular muscle and astrocytes. These
different channel forms have different pore properties and
adenine nucleotide sensitivity.
Recently, Gloyn et al. reported in an ethnically diverse
patient cohort that six heterozygous activating mutations
in the KCNJ11 gene encoding the Kir6.2 subunit of the
pancreatic β-cell potassium ATP (KATP) channel caused
PNDM in ten probands [18]. Some of these mutations are
also associated with developmental delay, muscle weak-
ness and epilepsy [18]. We screened the KCNJ11 gene for
mutations in patients with PNDM recruited through the
French network for the study of neonatal diabetes. Seven-
teen at-term babies with a median age of 64 days at diag-
nosis of diabetes (range 1–260) were included [19]. We
identified seven heterozygous non-synonymous muta-
tions in nine patients: three (V59M, R201C, R201H) were
already described by Gloyn et al.; the four novel mutations
resulted in amino acid changes of Kir6.2 at positions
F35L, G53N, E322K, Y330C. More patients with a Kir6.2
mutation (6/9) were reported to have a smaller birth
weight than those without the mutation (2/8), confirm-
ing the findings of Gloyn et al. [18,19]. These mutations
lead to a permanent opening of the potassium channel,
therefore preventing any activation of the voltage-depend-
ent calcium channel and any glucose-induced insulin
secretion (Figures 5 and 6). Although Kir6.2 mutation car-
riers do not represent a phenotypically specific form of
PNDM, an impaired function of Kir6.2 is associated with
in utero insulin secretory insufficiency and growth retarda-
tion. In conclusion, Kir6.2 mutations are a common
cause, from one third to a half of PNDM in Caucasians.
This work has opened new avenues for the work-up and
treatment of those patients (see below) [20].
Mutations in ABCC8 encoding the SUR1 subunit of the pancreatic 
KATP channel
As explained above, the ATP-gated potassium (KATP) chan-
nel (composed of SUR1 and KIR6.2 proteins) is a key reg-
Dup(6)(q24): Inheritance of 2 paternal alleles (F1+F2)Figure 2
Dup(6)(q24): Inheritance of 2 paternal alleles (F1+F2). M (mother), F (father).Page 4 of 11
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adenine nucleotides to KIR6.2 leading to closing of the
channel, and activated by nucleotide binding and/or
hydrolysis on SUR1 leading to opening of the channel.
The balance of these opposing actions determines the low
open channel probability, P0, which controls the excita-
bility of pancreatic β-cells. We hypothesized that activat-
ing mutations in ABCC8 which encodes SUR1 cause
neonatal diabetes. We therefore screened the 39 exons of
ABCC8 in 34 patients diagnosed with permanent or tran-
sient neonatal diabetes (ND) of unknown origin in a case
series of 73 ND patients [21]. We assayed the electrophys-
iological activity of mutant and wild-type KATP channels.
We identified seven missense mutations in nine patients.
Four mutations were familial and showed vertical trans-
mission with neonatal and adult onset diabetes; the
remaining mutations were de novo and not found in more
than 300 non-diabetic or early onset diabetic subjects of
similar genetic background. Mutant channels in intact
cells and in physiologic concentrations of MgATP had a
markedly higher P0 compared with wild type channels.
These over-active channels retained sulfonylurea sensitiv-
ity and treatment with sulfonylureas achieved euglycemia.
Dominant mutations in ABCC8 account for 12% (9/73)
of our ND cases. Diabetes results from a novel mechanism
whereby the basal Mg-nucleotide-dependent stimulatory
action of SUR1 on the KIR pore is elevated and block by
sulfonylureas is preserved [21] (Figures 5 and 6).
B2. "Transient" and permanent neonatal diabetes: a common 
molecular mechanism?
The clinical difference between a transient and a perma-
nent form of neonatal diabetes is not always accounted
for by a different molecular mechanism. The methylation
anomalies (chromosome 6q anomalies) have not so far
been found to be associated with permanent neonatal dia-
betes. On the contrary, mutations in the SUR1 and Kir6.2
subunit have been found in association with transient and
permanent neonatal diabetes. Of note is that mutations in
Kir6.2 have been found mostly in association with very
early forms of diabetes, usually before 6 months of age,
whereas the phenotypic variability of SUR1 mutations is
broader [21,22]. Indeed, mutations in SUR1 can be linked
to ketoacidosis in a newborn, as well as to bona fide type 2
diabetes in a young adult [21].
III. Syndromes associated with PNDM
A number of discrete clinical syndromes have been iden-
tified as associated with PNDM.
Dup(6)(q24): Increase dosage of one paternal allele (F1)Figure 3
Dup(6)(q24): Increase dosage of one paternal allele (F1). M (mother), F (father), h (peak height).Page 5 of 11
(page number not for citation purposes)
Orphanet Journal of Rare Diseases 2007, 2:12 http://www.OJRD.com/content/2/1/12A. Pancreas agenesis and the Insulin Promoter Factor-1 
(IPF1) gene
The first patient described was a child with pancreatic
agenesis and marked endocrine and exocrine failure. Insu-
lin Promoter Factor-1 appeared to be a good candidate for
pancreatic agenesis, given its role as a master control of
exocrine and endocrine pancreatic development identi-
fied from studies of gene disruption [23], and later, as a
regulator of insulin and somatostatin gene expression
[24]. The child was homozygous for a single nucleotide
deletion within codon 63 of IPF-1 (Pro63fsdelC) [25].
Furthermore, eight individuals from six generations with
early onset diabetes akin to type 2 diabetes have been
identified within the extended family. These were identi-
fied as heterozygotes for the same mutation, with the
mutant truncated isoform of IPF-1 acting as a dominant
negative inhibitor of wild type IPF-1 activity [26]. The ill-
ness resulting from heterozygosity was reassigned as
Maturity Onset Diabetes of the Young (MODY) 4. Addi-
tional studies have also identified that less severe IPF-1
mutations can cause autosomal dominant late onset
forms of type 2 diabetes that account for around 6% of a
French cohort of multiplex type 2 diabetic families.
B. Anomalies at the homozygous state in the Glucokinase 
gene
MODY 2 is caused by mutations in the glucokinase gene
and usually leads to mild hyperglycemia in affected indi-
viduals [27]. Glucokinase is a key regulator of glucose
PCR after digestion of the DNA with a methylation sensitive enzymeFigur  4
PCR after digestion of the DNA with a methylation sensitive 
enzyme. In the case of a methylation defect, one loses the 
amplicon normally present and due to the maternal methyl-
ated allele.
Heterozygous activating mutations in the KCNJ11 and ABCC8 gen s encoding the Kir6.2 and SUR1 subunit of the pancre-atic beta-cell po assium ATP (KATP) c an el caus PNDMFigu  6
Heterozygous activating mutations in the KCNJ11 and ABCC8 
genes encoding the Kir6.2 and SUR1 subunit of the pancre-
atic beta-cell potassium ATP (KATP) channel cause PNDM. 
This mutations led to an increase probability of opening of 
the potassium channel therefore preventing any activation of 
the voltage dependent calcium channel and any glucose 
induced insulin secretion.
Insulin secretion in relation to the potassium channel encoded for by KCNJ11 and ABCC8 in  nor al subj ctFigur  5
Insulin secretion in relation to the potassium channel 
encoded for by KCNJ11 and ABCC8 in a normal subject.Page 6 of 11
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secretion. However, within two families (one Norwegian
and one Italian) with multiple forms of diabetes in their
pedigree, two infants with classical PNDM (presenting on
day one) have been identified. They were homozygous for
missense mutations within the glucokinase gene; this ren-
dered them completely deficient in glycolytic activity,
whilst their apparently consanguineous and mild to mod-
erately glucose intolerant parents were heterozygous for
the same mutations [28]. A search for further permanent
neonatal diabetes cases caused by homozygosity in glu-
cokinase mutations both in British and French cohorts
(total number 18) has yielded none suggesting that this is
unlikely to be a major cause of PNDM [29,30]. However,
we would recommend that if there is a history of gesta-
tional diabetes, testing for fasting glucose levels in both
parents is needed. If both parents have mild glucose intol-
erance, a screen for glucokinase mutations is then war-
ranted.
C. IPEX syndrome and FOXP3 gene
A number of authors have reported an X-linked syndrome
with a combination of exfoliative dermatitis, intractable
diarrhea with villous atrophy, hemolytic anemia, autoim-
mune thyroid disease and neonatal onset diabetes. Most
children die in the first year of life with overwhelming sep-
sis [31]. In some of these cases, agenesis of the islets of
Langerhans has been described [32]. The idea of an
autoimmune basis to this disease was strengthened by the
apparent success of cyclosporin A therapy in improving
the condition of one or two cases [33]. Identification of
Glutamic Acid Decarboxylase (GAD) antibodies in a
patient with this condition prior to bone marrow trans-
plantation suggests that this may be a form of neonatal
diabetes with an autoimmune origin. Bone marrow trans-
plantation conditioning (anti-T lymphocyte globulin,
busulfan and cyclophosphamide) led to disappearance of
the diabetes a week before transplantation. Subsequently,
the diarrhea resolved, as did the dermatitis. The patient
remained in remission for two years prior to the develop-
ment of a hemophagocytic syndrome that proved fatal
[34]. The mutation in this condition lies in the FOXP3
gene that encodes a forkhead domain-containing protein
[35]. The scurfy mouse with a frame-shift mutation in
Foxp3 is characterized by over-proliferation of CD4+/
CD8-T lymphocytes with multi-organ infiltration. The
males die 15–25 days after birth [9]. It has now been dem-
onstrated that the protein product 'scurfin' is essential for
normal immune homeostasis.
D. Wolcott-Rallison and EIF2AK3 gene
Wolcott-Rallison syndrome is an autosomal recessive dis-
order characterized by infancy onset (often within the
neonatal period) diabetes associated with a spondyloepi-
physeal dysplasia. In addition, there is a constellation of
other features such as hepatomegaly, mental retardation,
renal failure and early death [36]. In 2000, Delepine et al.
used two consanguineous families to map the condition
to the locus 2p12 [37]. Within this locus lays the gene
EIF2AK3 that is highly expressed in islet cells and acts as a
regulator of protein synthesis. Proteins and insulin are
manufactured in the endoplasmic reticulum (ER). In
response to environmental stresses, cells down regulate
protein synthesis by phosphorylation of the alpha subunit
of eukaryotic translation initiation factor-2 (eif2-alpha)
by eukaryotic translation initiation factor-2 kinase3
(EIF2AK3). Mal-folded proteins in the ER inhibit further
translation initiation mediated by increased phosphoryla-
tion of eif2-alpha. A targeted mutation of the mouse
Eif2ak3 gene (PERK) led to an accumulation of mal-
folded proteins in the ER, with resultant abnormally ele-
vated protein synthesis and increased stress on ER folding
machinery [38]. PERK is highly expressed in mouse pan-
creas. The PERK knock-out mouse demonstrates normal
pancreatic endocrine and exocrine development. How-
ever, postnatally the mice develop ER distension, accom-
panied by increased cell death and progressive diabetes
mellitus and pancreatic exocrine failure [39]. Further anal-
ysis within the consanguineous Wolcott-Rallison families
confirmed frameshift or amino-acid substitution muta-
tions occurring in EIF2AK3 segregating with the disorder
in each family [37].
E. Other syndromes with PNDM
In 1992, Christen et al. described two boys with X-linked
phosphoribosyl-ATP pyrophosphatase hyperactivity who
became diabetic on day one of life. Glucose intolerance
persisted throughout life, although there were periods off
insulin, as the children grew older. Both boys had other
major problems including mental retardation, ataxia and
progressive axonal neuropathy. The mother also had
hyperuricemia (gout) and glucose intolerance with a his-
tory of gestational diabetes [40].
In 1994, Yorifuji et al. described a condition of neonatal
diabetes associated with severe hypoplasia of the pancreas
(only head and uncus present) and congenital cyanotic
heart disease in a single family with apparent autosomal
dominant inheritance. Not all the cases developed diabe-
tes as a neonate, the timing is probably related to the size
of remaining pancreatic tissue [41].
Recently, another severe syndrome was described in
which three members of a consanguineous family devel-
oped neonatal diabetes and cerebellar hypoplasia. An
autosomal recessive inheritance pattern was suggested.
The infants all died within a few months of birth from a
combination of metabolic dysfunction, respiratory com-
promise and sepsis [42]. Interestingly, there are a number
of specific transcriptional activators which regulate genePage 7 of 11
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dysfunction of any of these might explain the two compo-
nents of this syndrome [43]. Indeed, this syndrome was
found to be linked to mutations in the PTF1A transcrip-
tion factor, a major gene involved in pancreatic develop-
ment and also expressed in the cerebellum [44]. These
patients have pancreatic hypoplasia associated with
microcephaly linked to cerebellar hypoplasia [44].
Very recently, mutations in Glis3 (another transcription
factor) were found to explain a syndrome which associ-
ated neonatal diabetes, hypothyroidism, congenital glau-
coma, kidney cysts and hepatic fibrosis [45].
A single case report has suggested that maternal enterovi-
rus (echovirus 6) infection in pregnancy (end of first tri-
mester) can lead to autoimmune, neonatal onset diabetes
with the presence of anti-insulin and glutamic acid decar-
boxylase antibodies at birth or very soon after birth. In
this female child (ruling out IPEX), the pancreas was very
hypoplastic and the authors suggested a role for mater-
nally transmitted enterovirus either by direct influence on
pancreatic organogenesis or through aggressive β-cells tar-
geted autoimmune attack [46].
It is worth mentioning that neonatal diabetes may also
exist in the context of a mitochondrial disorder [6]. It is
usually associated with other organ dysfunction, which
may be recognized after the diabetes mellitus diagnosis.
IV. Clinical and biological diagnosis
A. Diagnosis of the "transient" or permanent nature of the 
neonatal diabetes
The following conclusions can be drawn from current
knowledge on neonatal diabetes mellitus: 1) Patients with
TNDM are more likely to have intrauterine growth retar-
dation and less likely to develop ketoacidosis than
patients with PNDM; 2) TNDM patients are younger at the
age of diagnosis of diabetes and have lower initial insulin
requirements; 3) Considerable overlap occurs between
the two groups, so that TNDM cannot be distinguished
from PNDM based on clinical features; 4) Very early onset
diabetes mellitus seems to be unrelated to autoimmunity
in most instances; 5) Recurrent diabetes is common in
patients with "transient" neonatal diabetes mellitus and,
consequently, prolonged follow-up is imperative; 6)
Molecular analysis of chromosome 6 anomalies, the
KCNJ11 and ABCC8 genes (encoding Kir6.2 and SUR1
respectively) provide a tool for identifying transient from
permanent neonatal diabetes mellitus in the neonatal
period; 7) About 50% of the PNDM cases are linked to
potassium channel mutation which has potentially
important therapeutic consequences leading to transfer
some patients from insulin therapy to sulfonylureas.
B. Methods for the molecular diagnosis of the 6q2-4 
anomalies associated with "transient" neonatal diabetes
The uniparental disomy of the chromosome 6 can be evi-
denced by the analysis of polymorphic markers present
on the chromosome 6; meiotic segregation of the chro-
mosomes can be determined by comparing the allelic pro-
files of polymorphic markers in the child and his parents.
Usually, a total uniparental disomy of the chromosome 6
is evidenced, but partial one can also be found. This is
why markers close to the region of interest (6q24) should
be chosen. Chromosome 6 duplications can also be evi-
denced by that technique (Figures 2 and 3) [13]. The use
of Polymerase Chain Reaction (PCR) after digestion of the
DNA with a methylation sensitive enzyme permits detec-
tion of methylation defects (Figure 4) [15].
Whatever the technique, the presence of a chromosome
6q anomaly predicts a "transient" form of the disease. Its
absence, however, does not rule out this form of neonatal
diabetes mellitus.
V. Treatment
A. Therapeutic consequences in the case of potassium 
channel mutation
The KATP channels have a central role in cell response to
metabolic changes in many organs and especially in pan-
creatic insulin secreting cell. The advances in the compre-
hension of the physiological function of these channels,
and in particular of the Kir6.2 and SUR1 subunits, has
found a major clinical application for patients having per-
manent neonatal diabetes due to a KCNJ11 or a ABCC8
mutation. The transfer from insulin injections to oral glib-
enclamide therapy seems highly effective for most
patients and safe [21,47]. This illuminates how the molec-
ular understanding of some monogenic form of diabetes
may lead to an unexpected change of the treatment in
children. This is a spectacular example of how the phar-
macogenomic approach improves in a tremendous way
the quality of life of the young diabetic patients. In France
and some others countries, the transfer of the patients
from insulin to sulfonylureas should be made within the
legal rules of the country, most often in the context of clin-
ical trials approved by the Health Authorities, as the sulfo-
nylureas are not licensed (even contra-indicated in same
countries) to be used in children. These legal aspects of
the treatment should not be under estimated due to
potential deleterious side effects of the sulfonylureas.
B. Management of the treatment of this very early onset 
type of diabetes, in the neonatal period
Insulin therapy is crucial in NDM to obtain satisfactory
weight gain and growth in newborns with intra-uterine
growth retardation. In some cases, glucose and caloric
deprivation has been instituted in newborns in the face of
hyperglycemia to avoid insulin therapy. This leads to fur-Page 8 of 11
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should be maintained in these newborns and insulin ther-
apy given. Although pediatricians face numerous difficul-
ties in managing insulin therapy in the newborn period,
very few data are available on the methods of insulin
delivery in neonatal diabetes. In infants with transient
neonatal diabetes mellitus, control of the blood glucose
concentration can be attained with ultralente insulin
treatment, without any episodes of hypoglycemia [48].
These authors recommended subcutaneous injection of
ultralente insulin, rather than lente or isophane (NPH)
insulin, to avoid hypoglycemia during the treatment of
transient neonatal diabetes mellitus. This has not been
our experience. Multiple injections of regular insulin are
sometimes difficult to manage. Short acting insulins, both
human and analogue, are best avoided except when using
intravenous soluble insulin infusions to initially stabilize
the infant. However in the UK, isophane insulin on a once
daily basis has afforded reasonable control. Potentially
the insulin analogue (insulin glargine) with its very
steady, flat pharmacokinetic profile might prove useful in
this condition, although there is currently no license for
children of this age.
In some centers in France, we have chosen the continuous
subcutaneous insulin infusion (CSII) in all the cases of
neonatal diabetes requiring subcutaneous insulin therapy
for more than 15 days. We report here our experience in
the five cases where initiation of the CSII was done in our
departments. Four of the cases were TNDM (follow-up 7
months to 10 years). The practical aspects of the treatment
were as follows. During the first days, the daily dose
requirement was evaluated with intravenous insulin and
glucose infusions. When good glycemic control was
obtained, CSII therapy was started. Insulin was diluted to
4 to 10 units per milliliter. Insulin strategy to start CSII
depended on the feeding conditions. Under enteral con-
tinuous feeding, 100% of the total daily dose was admin-
istered as basal rate. Under bottle feeding, the basal rate
represented 30% of the total daily dose and boluses 70%,
with the same insulin dose before each meal (number of
meals 8, then 7, then 6). Blood glucose was monitored
every 3 to 4 hours. Basal rate was adjusted on the night
blood glucose measurements and boluses on the post-
prandial ones. CSII therapy was started between day 7 and
55, one to 13 days after initiation of insulin therapy. Dur-
ing the first month of CSII therapy (dose at day 15 of CSII:
0.3 to 1 unit per kg/day), good glycemic control was
achieved on a mean number of 240 blood glucose meas-
urements (5 patients). Mean blood glucose was 1.73 g/l,
no severe hypoglycemia was noted, and the mean number
of hypoglycemia episodes (blood glucose <0.6 g/l) was
4.2 per month. Similar excellent results were achieved for
the rest of the CSII in both the TNDM and the PNDM
cases. We did not observe any cutaneous side effects. We
conclude that during the neonatal period, CSII therapy is
safe, more physiological, more accurate and easier to
manage than injections. CSII allows us to match the insu-
lin requirements of a newborn. CSII requires management
and supervision by a experienced team of physicians and
nurses.
Realizing how difficult it is to take care of a child of this
age with diabetes mellitus should prompt clinicians to
transfer these children to specialized centers. Insulin ther-
apy and high caloric intake are the basis of the treatment.
Insulin pump may offer an interesting therapeutic tool in
this age group in experienced hands.
VI. Genetic counseling
The risk of recurrence is different according to the "tran-
sient" or permanent form of the disease and to the differ-
ent molecular mechanisms identified.
Anomalies in the chromosome 6q region: a disease linked 
to imprinting
In the case of uniparental disomy, none of the allele of the
mother is found in the proband, the risk of recurrence
does not exist in theory and there is no transmission by
the child. Partial uniparental disomy have been described,
linked to a post-zygotic mechanism. The recurrence risk is
probably weak or close to zero, as the anomaly is post-
zygotic.
If partial duplication is present in the propositus, there is
a risk of disease recurrence in the family and parents have
to be tested. Carriers of the duplication have a 50% risk of
transmitting the defect. If it is a de novo mutation, there is
a priori no risk of recurrence, except if germinal mosaicism
exists (not described so far). Concerning the risk of trans-
mission, fathers will transmit both the genetic defect and
the disease. Half of the children will have the disease,
which will be present equally in boys and girls. If the
mother has the anomaly, her children will not have the
disease but the male offspring will eventually pass on the
disease.
Imprinting anomaly: the logic says that the mother
should pass it on (imprinting relaxation) but so far no
familial case is known and the risk of transmission is
unknown. Indeed, the cause of the imprinting relaxation
is not identified and the identified children with this
anomaly are too young to procreate.
Mendelien inheritance
Recurrence risk is 25% in the recessive autosomal disor-
ders (EIF2AK, Glis3, PTF1A, and PDX1 genes). IPEX syn-
drome is an X linked disorder.Page 9 of 11
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nel subunits are transmitted in the heterozygous state in a
dominant way. Moreover, transmission by germinal
mosaicism has here been described.
VII. Prognosis
In the neonatal period, the prognosis is linked to the
severity of the disease, the degree of dehydration and aci-
dosis, as well the rapidity with which the disease is recog-
nized and treated. In the following period, the prognosis
is determined by the associated malformations and
lesions. For example, in the case of potassium channel
anomalies, neuropsychological and neuromuscular dis-
turbances can be present. Finally, the prognosis rely on
the metabolic control, as in all the forms of diabetes mel-
litus, which will determine the timing of appearance of
the long standing diabetes complications.
VIII. Conclusions, unresolved questions
Neonatal diabetes is a rare condition. However, it is prob-
ably of great relevance to our understanding of the cause
of type 2 diabetes within the general population. We
believe these rare single gene disorders are natural models
for identifying new genes with possible relevance to type
2 diabetes. As discussed, the IPF-1 mutation is important
in MODY 4 and in some familial forms of early onset type
2 diabetes and the SUR1 mutation plays a role in newborn
diabetes as well as in type 2 diabetes in young adults. We
hope that elucidating the etiology of other forms of neo-
natal diabetes will provide information on normal pan-
creatic development and the basis of the pathology
underlying pancreatic dysfunction.
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